Document Detail

Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.
MedLine Citation:
PMID:  21533567     Owner:  NLM     Status:  Publisher    
Atrial fibrillation (AF) is well known as one of the leading causes of stroke and systemic embolism. Anticoagulation therapy is recommended in all patients at moderate-to-high risk of stroke. The vitamin K antagonist warfarin has traditionally been used in these patients but presents challenges in dosing and monitoring in these patients. The oral direct thrombin inhibitor dabigatran etexilate (Pradaxa®; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA) was recently approved for use in the US for preventing stroke and systemic embolism in patients with nonvalvular AF. Clinical trials have shown it to reduce the risk of stroke and systemic embolism when compared with warfarin (goal international normalized ratio [INR] 2-3) with a similar risk for severe bleeding. It can be given twice daily, with the dose adjusted for renal function. It does not have any dietary restrictions, has few drug interactions (except involving permeability [P]-glycoprotein [P-gp] agents), and does not require routine laboratory monitoring. Patients may experience significant dyspepsia with its use. Compared with warfarin there is increased risk for gastrointestinal bleeding and perhaps myocardial infarction. Currently, no reversal agent exists for use in situations of overdose or severe bleeding although some strategies have been suggested. Despite its high acquisition cost compared with warfarin, analysis using theoretical models has shown it to be cost-effective. Dabigatran offers a unique alternative to warfarin in patients with nonvalvular AF and can be beneficial in patients requiring anticoagulation therapy.
Stephen D Bendel; Robert Bona; William L Baker
Related Documents :
22354157 - An fp-cit pet comparison of the differences in dopaminergic neuronal loss between idiop...
6701717 - Malignant tumours of the breast. frequency distribution by age, race and stage at groot...
8273387 - Role of extracorporeal shock wave lithotripsy in hepato-biliary-pancreatic surgery.
6608067 - Treatment of pancreatic injuries.
10454777 - Aggressive treatment of severe idiopathic focal segmental glomerulosclerosis.
16330177 - C-reactive protein in patients on chronic hemodialysis with different techniques and di...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-26
Journal Detail:
Title:  Advances in therapy     Volume:  -     ISSN:  1865-8652     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-5-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Schools of Pharmacy and Medicine, Storrs and Farmington CT & Department of Hematology-Oncology, University of Connecticut, 263 Farmington Ave, MC2205, Farmington, CT, 06030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intraoperative interruption of an accessory pathway : Is it always a long-term cure for arrhythmia?
Next Document:  Outcome of intensive integrated intervention in participants with impaired glucose regulation in Chi...